Potential Biomea Fusion, Inc. ( NASDAQ:BMEA ) shareholders may wish to note that the Independent Director, Michael ...

International diabetes pioneers and thought leaders from 11 countries will work with Biomea leadership to unlock the potential of menin science and beta cell biology to advance BMF-219 and Biomea’s ...

I highlight potential of Biomea Fusion's diabetes drug amid competition, advises caution with stock due to risks. Read more ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 22.46% ...

Fintel reports that on September 27, 2024, Truist Securities upgraded their outlook for Biomea Fusion (NasdaqGS:BMEA) from ...

The U.S. FDA has approved Cobenfy, a dual M1/M4 muscarinic agonist that offers a fundamentally different approach to treating schizophrenia. The fixed dose combination of xanomeline-trospium is the ...

Joseph Pantginis, an analyst from H.C. Wainwright, maintained the Buy rating on Biomea Fusion (BMEA – Research Report). The associated ...

Biomea (BMEA) has received two analyst upgrades along with bullish comments from other firms following news the FDA has lifted a clinical hold on a study of its drug BMF-219.

Friday, the FDA lifted the clinical hold on Biomea Fusion, Inc.’s (NASDAQ:BMEA) ongoing Phase 1/2 clinical trials of the ...

Biomea Fusion, Inc. BMEA shares jumped 15.5% to $11.05. Biomea Fusion disclosed that the FDA lifted its clinical hold on ...

The U.S. FDA approved Bristol Myers' new schizophrenia drug, the first of its kind in decades. Bavarian Nordic signed an ...

On Thursday, Biomea Fusion Inc (BMEA) stock saw a modest uptick, ending the day at $9.57 which represents a slight increase of $0.80 or 9.12% from the prior close of $8.77. The stock opened at $8.98 ...